Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

A Northwestern Medicine study published in Nature Communications has revealed how HIV can protect infected cells by altering ...

Company to receive approximately $7 million in funding from the Gates Foundation to use its srRNA platform to develop malaria and HIV candidates to address two of the world's most persistent public ...

In individuals who started antiretroviral therapy during acute HIV infection, the proliferative capacity of HIV-specific CD8+ ...

Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

PHILADELPHIA, PA — The Wistar Institute has appointed Vincent Wu, Ph.D., as a Caspar Wistar Fellow within its Vaccine & Immunotherapy Center, bringing on a rising HIV researcher whose hybrid expertise ...

Enanta’s portfolio of RSV replication inhibitors with potential for first-in-disease and best-in-disease treatment.

On Aaliyah’s birthday, we honor her forever legacy through photos that capture her style, grace, and cultural impact. Explore ...

Researchers are edging closer to a universal antiviral drug, a single medicine that could treat every virus known to man.

Dr Ray O’Connor takes a look at recent clinical articles on the importance of promoting vaccines for Measles, HIV, Gonorrhoea ...

Alastair Crooke, a former British ambassador, stated in a recent interview in reference to European and American political ...